Literature DB >> 21471754

Transanal endoscopic microsurgery for residual rectal cancer after neoadjuvant chemoradiation therapy is associated with significant immediate pain and hospital readmission rates.

Rodrigo Oliva Perez1, Angelita Habr-Gama, Guilherme Pagin São Julião, Igor Proscurshim, Arceu Scanavini Neto, Joaquim Gama-Rodrigues.   

Abstract

BACKGROUND: Transanal endoscopic microsurgery may represent appropriate diagnostic and therapeutic procedure in selected patients with distal rectal cancer following neoadjuvant chemoradiation. Even though this procedure has been associated with low rates of postoperative complications, patients undergoing neoadjuvant chemoradiation seem to be at increased risk for suture line dehiscence. In this setting, we compared the clinical outcomes of patients undergoing transanal endoscopic microsurgery with and without neoadjuvant chemoradiation.
METHODS: Thirty-six consecutive patients were treated by transanal endoscopic microsurgery at a single institution. Twenty-three patients underwent local excision after neoadjuvant chemoradiation therapy for rectal adenocarcinoma, and 13 patients underwent local excision without any neoadjuvant treatment for benign and malignant rectal tumors. Chemoradiation therapy included 50.4 to 54 Gy and 5-fluorouracil-based chemotherapy. All patients underwent transanal endoscopic microsurgery with primary closure of the rectal defect. Complications (immediate and late) and readmission rates were compared between groups.
RESULTS: Overall, median hospital stay was 2 days. Immediate (30-d) complication rate was 44% for grade II/III complications. Patients undergoing neoadjuvant chemoradiation therapy were more likely to develop grade II/III immediate complications (56% vs 23%; P = .05). Overall, the 30-day readmission rate was 30%. Wound dehiscence was significantly more frequent among patients undergoing neoadjuvant chemoradiation therapy (70% vs 23%; P = .03). Patients undergoing neoadjuvant chemoradiation therapy were at significantly higher risk of requiring readmission (43% vs 7%; P = .02).
CONCLUSION: Transanal local excision with the use of endoscopic microsurgical approach may result in significant postoperative morbidity, wound dehiscence, and readmission rates, in particular, because of rectal pain secondary to wound dehiscence. In this setting, the benefits of this minimally invasive approach either for diagnostic or therapeutic purposes become significantly restricted to highly selected patients that can potentially avoid a major operation but will still face a significantly morbid and painful procedure.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21471754     DOI: 10.1007/DCR.0b013e3182083b84

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  31 in total

1.  Preoperative chemoradiotherapy affects postoperative outcomes and functional results in patients treated with transanal endoscopic microsurgery for rectal neoplasms.

Authors:  G Rizzo; D P Pafundi; F Sionne; L D'Agostino; G Pietricola; M A Gambacorta; V Valentini; C Coco
Journal:  Tech Coloproctol       Date:  2021-01-18       Impact factor: 3.781

Review 2.  Local Excision and Endoscopic Resections for Early Rectal Cancer.

Authors:  Guilherme Pagin São Julião; Juan Pablo Celentano; Flavia Andrea Alexandre; Bruna Borba Vailati
Journal:  Clin Colon Rectal Surg       Date:  2017-11-27

Review 3.  Organ-Preserving Strategies for the Management of Near-Complete Responses in Rectal Cancer after Neoadjuvant Chemoradiation.

Authors:  Patricio B Lynn; Paul Strombom; Julio Garcia-Aguilar
Journal:  Clin Colon Rectal Surg       Date:  2017-11-27

Review 4.  Transanal endoscopic microsurgery for rectal cancer: T1 and beyond? An evidence-based review.

Authors:  Marco E Allaix; Alberto Arezzo; Mario Morino
Journal:  Surg Endosc       Date:  2016-02-22       Impact factor: 4.584

5.  SSAT State-of-the-Art Conference: Advances in the Management of Rectal Cancer.

Authors:  Evie Carchman; Daniel I Chu; Gregory D Kennedy; Melanie Morris; Marc Dakermandji; John R T Monson; Laura Melina Fernandez; Rodrigo Oliva Perez; Alessandro Fichera; Marco E Allaix; David Liska
Journal:  J Gastrointest Surg       Date:  2018-09-13       Impact factor: 3.452

Review 6.  A systematic review of transanal minimally invasive surgery (TAMIS) from 2010 to 2013.

Authors:  B Martin-Perez; G D Andrade-Ribeiro; L Hunter; S Atallah
Journal:  Tech Coloproctol       Date:  2014-05-07       Impact factor: 3.781

Review 7.  Management of Rectal Polyps.

Authors:  Michelle L Cowan; Matthew L Silviera
Journal:  Clin Colon Rectal Surg       Date:  2016-12

8.  Non-inferiority multicenter prospective randomized controlled study of rectal cancer T2-T3s (superficial) N0, M0 undergoing neoadjuvant treatment and local excision (TEM) vs total mesorectal excision (TME).

Authors:  X Serra-Aracil; C Pericay; T Golda; L Mora; E Targarona; S Delgado; A Reina; F Vallribera; J M Enriquez-Navascues; S Serra-Pla; J C Garcia-Pacheco
Journal:  Int J Colorectal Dis       Date:  2017-12-12       Impact factor: 2.571

9.  Local excision of low rectal cancer treated by chemoradiotherapy: is it safe for all patients with suspicion of complete tumor response?

Authors:  Clotilde Debove; Nathalie Guedj; Ecoline Tribillon; Léon Maggiori; Magaly Zappa; Yves Panis
Journal:  Int J Colorectal Dis       Date:  2016-03-07       Impact factor: 2.571

10.  Transanal endoscopic microsurgery vs. laparoscopic total mesorectal excision for T2N0 rectal cancer.

Authors:  Marco Ettore Allaix; Alberto Arezzo; Giuseppe Giraudo; Mario Morino
Journal:  J Gastrointest Surg       Date:  2012-10-16       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.